< Philip Furmanski Ph.D. EOHSI Directory | EOHSI

Philip Furmanski Ph.D. » EOHSI Directory

A B C D E F G H I J K L M N O P R S T U W Y Z

Philip Furmanski Ph.D.

Distinguished Professor Rutgers University – Ernest Mario School of PharmacyEOHSI – Toxicology
Work William Levine Hall Room 215 160 Frelinghuysen Road Piscataway NJ 08854 Work Phone: 848-445-7244 Work Fax: 732-445-0687
Photo of Philip Furmanski Ph.D.

Biographical Info

Dr. Furmanski’s background is in cancer molecular and cell biology, mechanisms of tumor progression, experimental therapeutics of cancer and other invasive/infectious processes, preclinical and human clinical trials. He has expertise in a number of areas, including pathogenesis of environmental toxin-induced disease, role of macrophages in inflammatory processes related to environmental exposures, health effects of nanoparticles, genetic and epigenetic regulation of cellular functions, among others. As a result of long service to the scientific community on a number of Editorial Boards, grant review committees, advisory boards, he is very active as a mentor for junior faculty and those newly moving into the field (as well as more senior members) in many aspects of the scientific and administrative process, including interactions with industry (big pharma, biotech, materials and devices).

Scholarly Activities

  • Member and Inaugural Chair, Pathology C (Cancer Molecular Pathobiology/CAMP) Study Section, National Institutes of Health, June 2001 – October 2003
  • Member, Advisory Committee for Oncologic Sciences, Center for Scientific Review, National Institutes of Health, January – June 1999 – June 2000
  • Member, National Institutes of Health Reviewers Reserve, July 1993 – July 1998
  • Member, Pathology B Study Section, Division of Research Grants, National Institutes of Health, October 1988 – June 1993
  • Chairman, Cancer Biology and Immunology Contracts Review Committee, National Cancer                 Institute,   May 1985 – October 1987

Recent Publications

  1. Abratenko, P, Adams, C, Alrashed, M, An, R, Anthony, J, Asaadi, J, Ashkenazi, A, Auger, M, Balasubramanian, S, Baller, B et al.. First Measurement of Inclusive Muon Neutrino Charged Current Differential Cross Sections on Argon at E_{ν}∼0.8  GeV with the MicroBooNE Detector. Phys. Rev. Lett. 2019;123 (13):131801. doi: 10.1103/PhysRevLett.123.131801. PubMed PMID:31697542
  2. Furmanski, O, Nieves, MD, Doughty, ML. Controlled Cortical Impact Model of Mouse Brain Injury with Therapeutic Transplantation of Human Induced Pluripotent Stem Cell-Derived Neural Cells. J Vis Exp. 2019; (149):. doi: 10.3791/59561. PubMed PMID:31355806
  3. Yánez, DC, Lau, CI, Chawda, MM, Ross, S, Furmanski, AL, Crompton, T. Hedgehog signaling promotes TH2 differentiation in naive human CD4 T cells. J. Allergy Clin. Immunol. 2019;144 (5):1419-1423.e1. doi: 10.1016/j.jaci.2019.07.011. PubMed PMID:31351102 PubMed Central PMC6843897
  4. Xu, J, Xu, M, Wang, Y, Mathena, RP, Wen, J, Zhang, P, Furmanski, O, Mintz, CD. Anesthetics disrupt growth cone guidance cue sensing through actions on the GABAA α2 receptor mediated by the immature chloride gradient. Neurotoxicol Teratol. ;74 :106812. doi: 10.1016/j.ntt.2019.106812. PubMed PMID:31251980 PubMed Central PMC6650745
  5. Bi, Y, Liu, J, Furmanski, B, Zhao, H, Yu, J, Osgood, C, Ward, A, Keegan, P, Booth, BP, Rahman, A et al.. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective. Ann. Oncol. 2019;30 (4):644-651. doi: 10.1093/annonc/mdz037. PubMed PMID:30715147
  6. Lance, EI, Kronenbuerger, M, Cohen, JS, Furmanski, O, Singer, HS, Fatemi, A. Successful treatment of choreo-athetotic movements in a patient with an EEF1A2 gene variant. SAGE Open Med Case Rep. 2018;6 :2050313X18807622. doi: 10.1177/2050313X18807622. PubMed PMID:30377530 PubMed Central PMC6202747
  7. Yánez, DC, Sahni, H, Ross, S, Solanki, A, Lau, CI, Papaioannou, E, Barbarulo, A, Powell, R, Lange, UC, Adams, DJ et al.. IFITM proteins drive type 2 T helper cell differentiation and exacerbate allergic airway inflammation. Eur. J. Immunol. 2019;49 (1):66-78. doi: 10.1002/eji.201847692. PubMed PMID:30365177 PubMed Central PMC6396086
Search PubMed
Categories: Faculty, Toxicology
Updated 5 months ago.
Skip to toolbar